[Effect of continuous hemofiltration for treatment of multiple organ dysfunction syndrome after acute myocardial infarction in elderly patients].
OBJECTIVE
To study the effect of continuous hemofiltration (CH) on the prognosis of multiple organ dysfunction syndrome (MODS) after acute myocardial infarction (AMI) in elderly patients.


METHODS
Thirty-four elderly patients with MODS after AMI admitted to intensive care unit (ICU) were grouped into continuous hemofiltration (CH) group and non-CH (NCH) group. The Acute Physiology and Chronic Health Evaluation (APACHEII) scores and Marshall scores were assessed upon admission in ICU and 7 days after the admission. The mortality rates of the patients within 28 and 90 days after admission to ICU were calculated, and the changes in APACHEII scores and Marshall scores were compared between the two groups.


RESULTS
The APACHEII scores and Marshall scores showed no significant difference between the two upon admission to the ICU, but significantly decreased in CH group 7 days after the admission (P<0.05 and P<0.01 respectively). The APACHEII scores increased significantly in NCH group (P<0.01) 7 days after the admission while the Marshall scores remained unchanged (P>0.05). The overall mortality rates at 28 and 90 days were 41.18% and 61.76%, respectively. A significant difference was noted in the mortality rate at 28 days between the two groups (P<0.05), but not in the rate at 90 days (P>0.05).


CONCLUSIONS
CH can improve the organic functions and the short-term outcome of elderly patients with MODS after AMI, but has no positive effect on their long-term outcomes.
Yu
Zhou
Z
Medical Intensive Care Unit, Guangzhou General Hospital of Guangzhou Command, Guangzhou 510010, China. zhouyucn@163.com
Lai
Tian-shun
TS
Guo
Zhen-hui
ZH
D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006440:Hemofiltration; D006801:Humans; D008297:Male; D009102:Multiple Organ Failure / Q000150:complications / Q000628:therapy*; D009203:Myocardial Infarction / Q000150:complications / Q000628:therapy*; D011379:Prognosis